Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Sponsor: NGM Biopharmaceuticals, Inc
Summary
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Official title: A Phase 1 Dose Escalation/Dose Finding Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
130
Start Date
2022-03-31
Completion Date
2026-03
Last Updated
2024-10-10
Healthy Volunteers
No
Conditions
Interventions
NGM831
Drug: NGM831 NGM831 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.
NGM831 plus pembrolizumab (KEYTRUDA®)
Drug: NGM831 NGM831 is given intravenously (IV) every 3 weeks in a 21day cycle. Multiple dose levels will be evaluated. Drug: pembrolizumab (KEYTRUDA®) pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21day cycle.
NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
Drug: NGM831 NGM831 is given intravenously (IV) every 3 weeks in a 21-day cycle. Multiple dose levels will be evaluated. Drug: NGM438 NGM438 is given intravenously (IV) every 3 weeks in a 21-day cycle. Multiple dose levels will be evaluated. Drug: pembrolizumab (KEYTRUDA®) pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21-day cycle.
Locations (9)
NGM Clinical Study Site
Gilbert, Arizona, United States
NGM Clinical Study Site
Los Angeles, California, United States
NGM Clinical Study Site
Sarasota, Florida, United States
NGM Clinical Study Site
Tampa, Florida, United States
NGM Clinical Study Site
Grand Rapids, Michigan, United States
NGM Clinical Study Site
New York, New York, United States
NGM Clinical Study Site
Oklahoma City, Oklahoma, United States
NGM Clinical Study Site
Austin, Texas, United States
NGM Clinical Study Site
Houston, Texas, United States